SCHEMBL10003740

SCHEMBL10003740

CCOC(=O)c1c(OCC(F)(F)F)c2c(=O)n(-c3ccc(C(F)(F)F)cc3)c(CC)cc2n1C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.45
▸ ADORA1 P30542 1/20 0.38
▸ ALOX5 P09917 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ GAA P10253 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MLYCD O95822 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003872 0.95 SMO (0.40) SMOADORA1ALOX5MAPTGAA
SCHEMBL10004261 0.93 SMO (0.45) SMOMAPTGAAALDH1A1KDM4E
SCHEMBL10004932 0.93 SMO (0.50) SMOMAPTGAAALDH1A1KDM4E
SCHEMBL10004847 0.92 SMO (0.45) SMOMAPTALDH1A1KDM4ETP53
SCHEMBL10003374 0.90 SMO (0.47) SMO
SCHEMBL10004452 0.89 ADORA1 (0.38) SMOADORA1ALOX5MAPTGAA
SCHEMBL10004663 0.87 MAPT (0.41) ADORA1ALOX5MAPTGAAALDH1A1
SCHEMBL10004059 0.86 SMO (0.46) SMOMAPTGAAALDH1A1KDM4E
SCHEMBL10004430 0.85 PPARG (0.43) SMO
SCHEMBL10003808 0.85 GABRA2 (0.40) MAPTGAAALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471790-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-18 — — EP disclosed
US-8907089-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-09 — — US disclosed
US-20120220570-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471790-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220570-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SMO 1/4885ADORA1 2266/4885ALOX5 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback